Revolution Medicines Targets Hard-to-Treat Pancreatic Cancer With Two Early-Phase Readouts

Jefferies analyst Kelly Shi in a Sunday note to investors said that both data drops for Revolution Medicines’ experimental RAS inhibitors are positive and could be “synergistic” in the first-line setting for pancreatic ductal adenocarcinoma.